![]() |
CZECH MEDICAL ASSOCIATION J. Ev. PURKYNĚ |
Journals - Article | |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Česky / Czech version | Trans. Hemat. dnes, 11, 2005, No. 4, p. 10–13. |
Efficacy of rituximab as consolidation of first – line CHOP regimen
in patients with follicular lymphomas Belada D.1, Pytlík R.2, Trněný M.2, Malý J.1 1II. interní klinika, Fakultní nemocnice Hradec Králové, oddělení klinické hematologie, 2I. interní klinika VFN Praha |
|
Summary: Follicular lymphoma is the second most common type of lymphoma. First line treatment with chemotherapy can
lead to the clinical remission in part of patients but other patients have residual disease. The aim was to evaluate the
efficacy of monoclonal antibody anti CD20 – rituximab – as a consolidation therapy after induction treatment of
CHOP in patients with newly diagnosed follicular NHL. 40 patients with residual lymphoma after CHOP regimen
were treated with rituximab, either in monotherapy or in combination with salvage chemotherapy followed by high
dose therapy with stem cell support. We assessed efficacy and tolerance of the treatment. In 28 patients (70 %) complete
remission was achieved and no progression during treatment of rituximab was noticed. Toxicity of the treatment
was minimal. These results are encouraging for patients who not achieve CR after initial treatment of CHOP
regimen alone to extend lymphoma free period and improve their quality of life. But in September 2004 rituximab
was approved for the first line treatment of patients with follicular lymphoma in the Czech republic.
|
|
Order this issue
|
BACK TO CONTENTS | ||
| HOME PAGE | CODE PAGE | CZECH VERSION | |
© 1998 - 2008 CZECH MEDICAL ASSOCIATION J. E. PURKYNĚ |
Created by: NT Servis, s.r.o., hosted by P.E.S. consulting, s.r.o. |
WEBMASTER |